Diagnosis and therapy of chronic viral hepatitis;Diagnose und Therapie der chronischen Virushepatitis

Zeitschrift fur Gastroenterologie

Volumn 34, Issue 7, 1996, Pages 446-456

  Heintges, T ^a   Niederau, C ^a   Mohr, L ^a   Hensel, F ^a   Haussinger D ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

alfa interferon therapy; selection of patients; viral hepatitis

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; INTERFERON; PARACETAMOL;

ALOPECIA; AUTOIMMUNITY; CHRONIC HEPATITIS; DELTA AGENT HEPATITIS; DIARRHEA; HEPATITIS B; HEPATITIS C; HUMAN; INFLUENZA; NEUTROPENIA; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS HEPATITIS;

HEPATITIS, CHRONIC; HEPATITIS, VIRAL, HUMAN; HUMANS; INTERFERON TYPE I, RECOMBINANT; PROGNOSIS; TREATMENT OUTCOME;

EID: 0029977298     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Heintges T, Niederau C Epidemiologie und Klinik der chronischen Virushepatitis. Dtsch Med Wschr 1994; 119: 1365-70
2. Hadziyannis S, Wages J, Kim JP et al. Frequency of viremia with a new hepatitis virus (HGV) in patients with liver disease and in groups at high risk of exposure to blood and blood products. J Hepatol 1995; 25 (suppl. 1): 78
3. Stremmel W, Schwarzendrube J, Niederau C, Strohmeyer G. Epidemiology, clinical course, and treatment of chronic viral hepatitis. Hepatogastroenterol 1991, 38: 22-8
4. Rizetto M, Ponzetto A, Bonino F, Smedile A. Hepatitis delta virus infection: clinical and epidemiological aspects Viral Hepatitis and Liver Disease, New York, Alan R. Liss Inc. 1988, 389-94
5. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-5
6. Wands JR, Blum HE. Primary hepatocellular carcinoma N Engl J Med 1991; 325: 729-31
7. Kremsdorf D, Brechot C. Genetic variability of hepatitis B virus: potential clinical implications In: Meyer zum Büschenfelde KH, Hoofnagle J, Manns M (eds). Immunology and liver, Dordrecht, Netherlands: Kluwer, 1993; 61-82
8. Anderson MG, Murray-Lyon IM. Natural history of the HBsAg carrier. Gut 1985; 26: 848
9. Baker BL, Di Bisceglie A, Kaneko S et al Determination of hepatitis B virus DNA in serum using the polymerase chain reaction: clinical significance and correlation with serological and biochemical markers. Hepatology 1991; 13: 632-6
10. Korenman J, Baker B, Waggoner JG, Di Bisceglie A, Hoofnagle JH, In chronic hepatitis B loss of serum hepatitis B viral DNA (HBV DNA) usually occurs at the time of loss of hepatitis B surface antigen (HBs-Ag). Hepatology 1990; 12: 846
11. Angus PW, Locarnini SA, McCaughan GW et al. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 1995; 21: 14-8
12. Ishak K, Baptista L, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9
13. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5
14. Heintges T, Niederau C, Borchard F, Strohmeyer G. Should a liver biopsy routinely be performed prior to interferon (IFN) therapy in chronic viral hepatitis? J Hepatol 1993; 18 (suppl. 1): S 129
15. Heintges T, Niederau C, Mohr L et al. Liver biopsy prior to interferon therapy in chronic viral hepatitis. Zur Publikation eingereicht
16. Niederau C, Heintges T, Niederau M, Stremmel W, Strohmeyer G. Auswahl der Patienten mit chronischer Hepatitis B für eine Therapie mit Alpha-Interferon. Zärztl Fortbild 1993; 87: 273-8
17. Carmann WF, Jacyna MR, Hadziyanis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; ii: 588-90
18. Okamoto H, Yotsumoto S, Akahane Y et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64: 1298-303
19. Tillmann H, Trautwein C, Walker D et al. Clinical relevance of mutations in the precore genome of the hepatitis B virus Gut 1995; 37: 568-73
20. Hamasaki K, Nakata K, Nagayama Y et al. Changes in the prevalence of HBe-Ag-negative mutant hepatitis B virus during the course of chronic hepatitis B Hepatology 1994; 20: 8-14
21. Heintges T, Niederau C, Schaffrath B et al Quantification of precore-mutant hepatitis B viral strains in patients with chronic hepatitis B Manuskript in Vorbereitung
22. Zarski JP, Marcellin P, Cohard M et al. Comparison of anti-HBe-positive and HBe-antigen-positive hepatitis B in France. J Hepatol 1994, 20: 636-40
23. Lai ME, Solinas A, Mazzoleni AP et al The role of precore hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. J Hepatol 1994, 20 773-81
24. Carman WF, Fagan EA, Hadziyannis S et al Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991; 14. 219-22
25. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis N Engl J Med 1991, 324. 1699-704
26. Liang T, Hasegawa K, Rimon N, Wands J, Ben-Pourath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis N Engl J Med 1991, 324: 1705-9
27. Feray C, Gigou M, Samuel D et al. Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France J Hepatol 1993; 18: 119-22
28. Laskus T, Persing DH, Nowicki MJ, Mosley JW, Rakela J. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States Gastroenterology 1993; 105: 1173-8
29. Liang TJ, Hasegawa K, Munoz et al Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation. J Clin Invest 1994; 93: 550-5
30. Jardi R, Buti M, Cotrina M et al. Determination of hepatitis delta virus RNA by polymerase chain reaction in acute and chronic delty infection Hepatology 1995; 21: 25-9
31. Wu JC, Chen TZ, Huang YS et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction Gastroenterology 1995; 108: 796-802
32. Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992; 15: 350-3
33. Kuo G, Choo OL, Alter JH. An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science 1989; 244: 362-4
34. Nagayama R, Tsuda F, Okamoto H et al. Genotype dependence of hepatitis C virus antibodies detectable by the first-generation enzyme-finked immunosorbent assay with C100-3 protein J Clin Invest 1993; 92: 1529-33
35. Prieto M, Olaso V, Verdu C et al. Does the healthy carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22: 413-7
36. Romeo JM, Ulrich PP, Busch MP, Vyas GN. Analysis of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors. Hepatology 1993; 17: 188-95
37. Shakil AO, Conry-Cantilena C, Alter HJ et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995; 123: 330-7
38. Van der Poel CL, Cuypers HTM, Reesink HW et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991; 337: 317-9
39. Peters T, Mohr L, Scheiffele F et al. Antibodies and viremia in acute post-transfusion hepatitis C: A prospective study. J Med Virol 1994; 42: 420-7
40. Damen M, Cuypers HTM, Zaaijer HL, Reesink HW, Niesters HGM, Lelie PN. Second international quality control study on an HCV-RNA reference panel (Eurohep 2). J Hepatol 1995; 23 (suppl. 1): 91
41. Zaaijer HL, Cuypers HTM, Reesink HW et al. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993; 341. 722-4
42. Heintges T, Mohr L, Niederau C et al Quantitative hepatitis C RNA polymerase chain reaction and detection with a DNA-Elisa. Zur Publikation eingereicht
43. Simmonds P, Zhang LQ, Watson HG et al. Hepatitis C quantification and sequenzing in blood products, hemophiliacs and drug users. Lancet 1990; 336: 1469-72
44. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 9717-21
45. Davis GL, Lau JYN, Urdea MS et al. Quantitative detection of hepatitis C virus RNA by a solid phase branched chain DNA amplification method, definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994, 19: 1337-41
46. Tanaka T, Lau JYN, Mizokami M et al. Simple fluorescent EIA for detection and quantification of hepatitis C viremia. Hepatology 1995; 22: 355
47. Haber MH, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995; 90: 1250-5
48. Brillanti S, Foli M, Gaiana S, Masci C, Miglioli M, Barbara L. Persistent hepatitis C viremia without liver disease Lancet 1993; 341: 464-5
49. Shindo M, Arai K, Sokawa Okuno T The virological and histological states of anti-hepatitis C virus-posititve subjects with normal liver biochemical values. Hepatology 1995; 22: 418-25
50. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Sem Liv Dis 1995; 15: 41-63
51. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-83
52. Okamoto H, Sugijama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73. 673-9
53. Göser T, Töx U, Möller HM, Arnold JC, Theilmann L. Bedeutung der Genotypen bei chronischer Hepatitis-C-Virusinfektion und Hepatitis-C-Virus-bedingter Leberzirrhose in Deutschland. Dtsch Med Wschr 1995; 120: 1070-3
54. Zeuzem S, Roth WK, Herrmann G. Virushepatitis C. Z Gastro 1995; 33: 117-32
55. Pol S, Thiers V, Nousbaum JB et al. The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology 1995; 108: 581-3
56. Feray C, Gigou M, Samuel D et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1088-96
57. Lau JYN, Mizokami M, Kolberg JA et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Inf Dis 1995; 171: 281-9
58. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20
59. Ishak K, Baptista L, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9
60. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5
61. Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995; 22: 112-4
62. Heintges T, Mohr L, Niederau C, Strohmeyer G. Diagnose und Therapie der autoimmunen Hepatitis Z Gastroentrol 1995; 33: 462-7
63. Heintges T, Niederau C. Differentiation between autoimmune hepatitis and hepatitis C virus related liver disease. Z Gastroenterol 1993; 31: 285-8
64. Hiramatsu N, Hayashi N, Haruna Y et al. Immunohistochemical detection of hepatitis C virus-infected hepatocytes in chronic liver disease with monoclonal antibodies to core, envelope and NS3 regions of the hepatitis C virus genome. Hepatology 1992; 16: 306-11
65. Magrin S, Craxi A, Fabiano C et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-α or corticosteroid treatment Hepatology 1994; 19: 273-9
66. Tanno H, Fay OH, Rojman JA, Palazzi J, Bessone F. HBeAg/anti-HBe seroconversion during and after protracted immunosuppressive treatment in type B chronic hepatitis. Viral hepatitis and liver disease. New York, Alan R, Liss Inc, 1988; 940-4
67. Ikeda T, Lever AML, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 1986; 6: 962-66
68. Niederau C, Heintges T, Niederau M, Stremmel W, Strohmeyer G Prospective randomized controlled trial of sequential treatment with corticoids and alfa-interferon versus treatment with interferon alone in patients with chronic active hepatitis B. Eur J Med 1992; 1 396-402
69. Niederau C, Heintges T. Therapie der chronischen Virushepatitis mit Interferon. Internist 1994; 35: 70-9
70. Pirovino M, Aguet M, Huber M, Altorfer J, Schmid M. Absence of detectable serum interferon in acute and chronic viral hepatitis. Hepatology 1986; 6: 645-7
71. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled trial. New Engl J Med 1989; 321: 1501-6
72. Di Bisceglie A, Martin P, Kasianides C et al Recombinant interferon alpha therapy for chronic hepatitis C. N Engl J Med 1989. 321 1506-10
73. Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B Gastroenterology 1988; 95: 1318-25
74. Perillo RP, Schiff ER, Davis GL et al. A randomized controlled trial of interferon alfa-2 b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301
75. Hess G, Weber C, Rossol S et al. Behandlung der Hepatitis B Surface Antigen (HBsAg)-positiven chronischen Hepatitis mit rekombinantem alpha-Interferon. Ergebnisse einer Phase-II-Studie. Z Gastroenterol 1988; 26: 380-7
76. Müller R, Baumgarten R, Markus R et al. Behandlung der chronischen Hepatitis B mit Interferon α-2 b. Dtsch Med Wschr 1990; 115: 403-7
77. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBe-Ag positive patients treated with α-interferon for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7
78. Blum HE, Maier KP, Strohmeyer G. Aktuelle Therapie der chronischen Virushepatitis. Dtsch Med Wschr 1995; 120: 295-300
79. Niederau C, Heintges T. Wie viele Patienten mit chronischer Virushepatitis kommen für eine Interferontherapie in Betracht? Eine prospektive Analyse einer Universitätsambulanz. Med Klin 1993; 88: 511-5
80. Brook MG, Karayiannis P, Thomas CT. Which patients with chronic hepatitis B virus infection will respond to interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-3
81. Perillo RP. Chronic hepatitis B: problem patients. J Hepatol 1995; 22 (suppl. 1): 45-8
82. Hoofnagle JH, Di Bisceglie AM, Waggner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterotogy 1993; 104: 116-21
83. Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845-50
84. Hadziannis S, Bramou T, Makris A et al. Interferon alfa-2 b treatment of HBe-Ag negative/serum HBV-DNA positive chronic hepatitis type B. J Hepatol 1990; 11 (suppl. 1): S 133-6
85. Hess G, Manns M, Hütteroth Th, Meyer zum Büschenfelde KH. Discontinuation of immunosuppressive therapy in HBsAg positive hepatitis. The effect on viral replication and on liver cell damage. Digestion 1987; 36: 47
86. Böker KHW, Ringe B, Krüger M, Pichlmayr R, Manns M. Prostaglandin plus famciclovir: a new concept for the treatment of severe hepatitis B after liver transplantation. J Hepatol 1996 (in press)
87. Chang CN, Doong SL, Zhou JH et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of 2′-3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication J Biol Chem 1992; 267: 13938-42
88. Fattovich G, Giustina G, Brollo L et al. Therapy for chronic hepatitis B with lymphoblastoid interferon-alpha and levamisole. Hepatology 1992; 16: 1115-9
89. Fried MW, Korenman JC, DiBisceglie AM et al A pilot study of 2′, 3′-Dideoxyinosine for the treatment of chronic hepatitis B Hepatology 1992; 16: 861-4
90. Janssen HLA, Berk L, Heijtink RA, Ten Kate FJW, Schalm SW. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B. results of a randomized placebo-controlled trial. Hepatology 1993; 17: 383-8
91. Trepo C, Rougier P, Bizollon T et al. Combination therapy with ARA-AMP and interferon of chronic active hepatitis B. J Hepatol 1991; 13: S 3
92. Ruiz-Moreno M, Rua MJ, Molina J et al. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991; 13: 1035-9
93. Barbera C, Bortolotti F, Crivellaro C et al. Recombinant interferon-α 2 a hastens the rate of HBe-Ag clearance in children with chronic hepatitis B. Hepatology 1994; 20: 287-90
94. Rosina F, Cozzolongo R. Interferon in HDV infection. Antiviral Res 1994; 24: 165-74
95. Rosina F, Pintus C, Meschievitz C, Rizetto M A randomized controlled trial of a 12-month course of recombinant human interferon-alfa in chronic delta (type D) hepatitis, a multicenter italian study. Hepatology 1991 13: 1052-6
96. Farci P, Mandas A, Coiana A, Lai ME et al. Treatment of chronic hepatitis D with interferon-alfa 2 a. N Engl J Med 1994; 330: 88-94
97. Kasahara A, Hayashi M, Oshita M et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21. 291-297
98. Niederau C, Heintges T, Häussinger D. Treatment of hepatitis C with α-interferon: an analysis of the literature. Hepatogastroenterology 1996, im Druck
99. Poynard T, Bedossa P, Chevallier M et al A comparison of three interferon alfa-2 b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-62
100. Reichard O, Foberg U, Fryden A et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2 b for 60 weeks. Hepatology 1994; 19: 280-5
101. Marceilin P, Boyer N, Giostra E et al. Recombinant human α-interferon in patients with chronic Non-A, Non-B hepatitis: a multicenter randomized controlled trial from france. Hepatology 1991; 13: 393-7
102. Qian C, Camps J, Maluenda MD, Civeira MP, Prieto J. Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alpha-interferon therapy. J Hepatol 1992; 16: 380-3
103. Zignego AL, Macchia D, Monti M et al. Infection of peripheral mononuclear blood ceus by hepatitis C virus. J Hepatol 1992; 15: 382-6
104. Roffi L, Mels C, Antonelli G et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management. Hepatology 1995; 21: 645-9
105. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94
106. Yamada G, Takahashi M, Miyamoto R et al. Prediction of interferon effect in chronic hepatitis C by both quantification and gene-typing of HCV-RNA. Dig Dis Sci 1994; 39: 441-4
107. Yoshioka K, Kakumu S, Wakita T et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9
108. Yuki N, Hayashi N, Kasahara A et al. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 1995; 22: 457-63
109. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3
110. Hayashi H, Takikawa T, Nishimura N, Yano M. Improvement of serum aminotransferase levels alter phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-8
111. Olynyk JK, Rajender Reddy K, Di Bisceglie AM et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1992; 108, 1104-9
112. Van Thiel DH, Friedlander L, Fagiuoli S et al. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410
113. Mauss S, Heintges T, Adams O et al. Treatment of chronic hepatitis C with interferon α-2 b in patients infected with the human immunodeficiency virus. Hepatogastroenterol 1995; 42: 528-34
114. Martell M, Esteban JI, Quer J et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispezies nature of HCV genome distribution J Virol 1992; 66: 3225-9
115. Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16: 619-24
116. Moribe T, Hayashi N, Kanazawa Y et al Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995; 108. 789-95
117. Enomoto N, Sato C, Kurosaki M, Marumo F. Hepatitis C virus after tnterferon treatment has the variation in the hypervariable region of envelope 2 gene. J Hepatol 1994; 20: 252-61
118. Nishigucni S, Kuroki T, Morimoto et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-55
119. Boucher E, Jouanolle H, Andre P et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322-7
120. Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993; 19: 408-12
121. Reichard O, Yun ZB, Sonnerborg A, Weiland O. Hepatitis C viral RNA in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41: 99-102
122. Brillanti S, Garson J, Foli M et al A pilot study of combination therapy with ribavirin plus interferon alfa for interferant alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107. 812-7
123. Ruiz-Moreno M, Rua MJ, Castillo I et al. Treatment of children with chronic hepatitis C with recombinant interferon-alpha: a pilot study. Hepatology 1992; 16: 882-5
124. Lisker-Melman M, Di Bisceglie AM, Usala SJ et al Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102: 2155-60
125. Mayet WJ, Hess G, Gerken G et al. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatol 1989; 10: 24-8
126. Lenzi M, Ballardini G, Fusconi M et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 1990; 335: 258-9
127. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102: 1406-8